Le rapport d'activité Inserm 2018 vient de paraitre
Parmi les avancées scientifiques de l'année 2018, en page 9, un article sur les travaux de l'équipe d'Eric VIVIER du Centre d'Immunologie de Marseille-Luminy : Un nouvel anticorps efficace contre le cancer de la tête et du cou... Voir le rapport
His work on the characterization of molecules associated with T lymphocyte activation using monoclonal antibodies helped to position the Centre d’Immunologie de Marseille-Luminy (CIML) on the map of global immunology during the 1980s to 2000s..
Michel PIERRES, a world-renowned physician and immunologist, died on June 14, 2019
One of the first team leaders of the CIML, Michel Pierres was director of the centre from 1991 to 1995. His work on the characterization of molecules associated with T lymphocyte activation using monoclonal antibodies helped to position the Centre d’Immunologie de Marseille-Luminy (CIML) on the map of global immunology during the 1980s to 2000s... See Headline
A study by the Bernard Malissen (CIML CNRS, Inserm, AMU Marseille), M. Gstaiger (IMSB) and R. Aebersold (IMSB) groups which appeared in Cell Reports, identifies using proteomics and mouse models molecular mechanisms that might account for some of the failures observed during immunotherapy... CIML Headline
Immunotherapy shows spectacular success in treating cancers, but unfortunately only in a minority of patients. A study by the Gstaiger (IMSB), Aebersold (IMSB), and Malissen group (CIML CNRS, Inserm, AMU Marseille), which appeared in Cell Reports, identifies using proteomics and mouse models molecular mechanisms that might account for some of the failures observed during immunotherapy.
